EA
VRTX icon

Evolution Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Evolution Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+1
New +$443 ﹤0.01% 881
2023
Q3 		– Sell
-4
Closed -$1K – 167
2023
Q2 		$1K Hold
4
– – ﹤0.01% 145
2023
Q1 		$1K Buy
+4
New +$1.2K ﹤0.01% 137

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Evolution Advisers's VRTX Position: Q2 2026 in Review

Evolution Advisers opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 1 share worth $0. The stake represents ﹤0.01% of the portfolio and ranks #881 among its holdings. This is a return to the name: Evolution Advisers previously reported a position in VRTX as recently as Q2 2023.

Evolution Advisers first reported a position in VRTX in Q1 2023 and has held it in 3 quarters since. The position peaked at $1K in Q2 2023. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Evolution Advisers held 1 share of Vertex Pharmaceuticals worth $0 as of Q2 2026.
  • Vertex Pharmaceuticals was a new Evolution Advisers position in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #881 holding.
  • Evolution Advisers first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 3 quarters since.
  • Evolution Advisers's Vertex Pharmaceuticals position peaked at $1K in Q2 2023.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.